

DOCKET NO.:NPCI-0294/719-127CON3 1 -

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In Re Application of:

Raja Achari et al.

Serial No.: Not yet Assigned

Group Art Unit: Not yet Assigned

Filing Date: Herewith

Examiner: Not yet Assigned

For: Nasal Delivery of Apomorphine

EXPRESS MAIL LABEL NO: EL695382480US
DATE OF DEPOSIT: January 31, 2002

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL NO. EL695382480US,
POSTAGE PREPAID ON THE DATE INDICATED
ABOVE AND IS ADDRESSED TO BOX PATENT
APPLICATION, COMMISSIONER FOR PATENTS,
WASHINGTON,
D.C. 20231.

TYPED NAME: Jeffrey J. King
REGISTRATION NO.: 38,515

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).



In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date

of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.


- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:
 - ☐ Certification in Accordance with §1.97(e) is attached; or
 - ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
 - ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:
 - ☐ Certification in Accordance with §1.97(e) is attached; or
 - ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
 - ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).
 - ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
 - ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith.
- EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C§120 have been made in the instant application:
- ☒ Copies of references AA-AH listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/334,304, filed June 16, 1999.
- ☒ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references that are not in the English language.

Date:



Jeffrey J. King
Registration No. 38,515

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. NPCI-0294/719-127CON3		Serial No. Not yet Assigned	
				Applicant Raja Achari et al.			
				Filing Date Herewith		Group Not yet Assigned	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	AA	5,756,483	05/26/1998	Merkus	514	58	
	AB	5,770,606	06/23/1998	El-Rashidy et al.	514	284	
	AC	5,773,020	06/30/1998	Place et al.	424	426	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
	AD	WO 99/27905	06/10/1999	United Kingdom			
	AE	WO 99/66933	12/29/1999	PCT			
EXAMINER				DATE CONSIDERED			

1c997 U.S. PTO
 10/062290
 01/31/02

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. NPCI-0294/719-127CON3	Serial No. Not yet Assigned
		Applicant Raja Achari et al.	
		Filing Date Herewith	Group Not yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AF	Muñoz et al., "Long-term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations", <i>Clin Neuropharmacol</i> , 20(3):245-252, June 1997.	
	AG	Van Laar T. et al., "Nasolabial allergic reaction to intranasal administration of apomorphine in Parkinson Disease", <i>Ned Tijdschr Geneesk</i> , 136(14):702-4, April 4, 1992. Dutch (Abstract in English).	
	AH	Heaton et al., "Recovery of erectile function by the oral administration of apomorphine", <i>Urology</i> , 45(2):200-6, February 1995.	
EXAMINER		DATE CONSIDERED	